Lucid Diagnostics Inc. filings document a commercial-stage medical diagnostics issuer focused on esophageal precancer detection, its public-company governance, and its capital structure. Its 8-K reports disclose operating results and business updates for EsoGuard and EsoCheck, Regulation FD communications, completed common stock offerings, shelf registration statement references, proceeds for working capital and general corporate purposes, and related exhibits.
Proxy materials cover annual meeting matters, director elections, board classification, and stockholder voting. Other material-event filings address board appointments, non-employee director compensation arrangements, indemnification agreements, and governance rights associated with holders of the company’s convertible secured promissory notes due 2029.
Lucid Diagnostics Inc. (LUCD) reported third-quarter revenue of $1.203 million, versus $1.211 million a year earlier, and a $6.677 million net loss attributable to common stockholders, versus $10.397 million. For the nine months, revenue was $3.932 million versus $3.202 million; net loss was $32.273 million versus $41.744 million, and net cash used in operating activities was $38.948 million versus $33.907 million.
At September 30, 2026, cash was $17.993 million and working capital was approximately $4.3 million, including $17.3 million of current convertible notes. Management said recurring losses, negative operating cash flows and dependence on reimbursement, revenue growth and additional financing raise substantial doubt about the company’s ability to continue as a going concern within one year after the statements are issued. Medicare payments for EsoGuard tests at its Irving lab were received at $1,938.01 per test.
After quarter-end, Lucid sold 15,000 Series C preferred shares for approximately $15.0 million in gross proceeds; $1.6 million remained as subscription receivable as of November 10, 2026. The shares carry 20% annual dividends payable in common stock and a $0.3519 initial conversion price. Nasdaq gave Lucid until April 12, 2027 to regain its $1 minimum bid-price requirement.
Lucid Diagnostics Inc. reported third-quarter 2026 results and a Medicare reimbursement milestone for EsoGuard. The company says Medicare beneficiaries nationwide now have fully reimbursed access. Lucid reported first Medicare payments in October at the established Clinical Laboratory Fee Schedule rate of $1,938.01 per test; payments are through claim-by-claim adjudication and independent of the pending MolDX Local Coverage Determination reconsideration. Lucid performed 2,871 EsoGuard tests in the quarter and reported more than 1,800 tests in October, a record monthly volume.
Revenue was $1.203 million for the quarter, compared with $1.211 million a year earlier. GAAP net loss was $6.677 million, versus $10.397 million. Non-GAAP adjusted loss was $10.599 million. Cash and cash equivalents were $18.0 million as of September 30, 2026; after quarter-end, the company closed a $15.0 million Series C Convertible Preferred Stock financing. Lucid also launched its first two U.S. Department of Veterans Affairs programs and said five Concert client health plans, including three previously reported, are expected to have formally adopted its coverage policy by year-end.
Lucid Diagnostics Inc. (LUCD) completed an exempt sale to accredited investors of 15,000 shares of Series C Convertible Preferred Stock at $1,000 per share, generating approximately $15.0 million in gross proceeds.
Each preferred share is convertible at the holder’s option at an initial conversion price of $0.3519, subject to beneficial-ownership and Nasdaq primary-market limits. The preferred stock carries a 20% annual dividend, payable in common shares quarterly from December 31, 2026, through March 31, 2030. For dividends payable after April 1, 2027, a specified market-value shortfall is added to stated value or, at the company’s election and if permitted under its senior debt terms, may be paid in cash. In liquidation, holders receive the greater of 300% of stated value plus accrued unpaid dividends or the as-converted amount.
The Nasdaq primary-market limit is 19.99% of outstanding common stock, measured as of October 21, 2026, or, if earlier, the date of a definitive agreement for an aggregated transaction; it does not apply if stockholder approval is not required or has been obtained. The company also reduced the conversion price on its 12.0% senior secured convertible notes due 2029 to $0.3519 and agreed to register for resale common shares issuable upon conversion and dividend payments. Majority holders may designate one director while 25% of the original Series C remains outstanding, subject to stated limitations.
Lucid Diagnostics Inc. received a Nasdaq notice that its closing bid price had been below the $1 per-share minimum for 30 consecutive business days through October 9, 2026. Nasdaq gave the company until April 12, 2027, an initial 180-calendar-day period, to regain compliance by closing at or above $1 for at least 10 consecutive business days.
If Lucid does not regain compliance, it may be eligible for an additional 180-day period. If it is not eligible, or Nasdaq staff believes it will not be able to cure the deficiency, Nasdaq will provide notice after the initial period that the securities will be subject to delisting. The notice does not currently affect the listing, and LUCD will continue trading uninterrupted.
Lucid Diagnostics Inc. (LUCD) reports progress in payment, billing, and coding pathways for its EsoGuard Esophageal DNA Test and EsoCheck cell collection device. A Medicare Advisory Panel recommended maintaining EsoGuard’s original gapfill payment basis under the Clinical Laboratory Fee Schedule, with final CMS determinations expected in November after public comment.
The AMA CPT Editorial Panel approved a new Category III CPT code for nonendoscopic esophageal cell collection procedures performed with EsoCheck, enabling reporting and tracking once effective. The CDC/NCHS ICD-10 Coordination and Maintenance Committee gave a favorable response to a proposed new diagnosis code R85.83 for positive EsoGuard results, which the company expects to be finalized after public comment. Lucid will begin submitting Medicare claims under PLA code 0114U this month for tests at its Texas laboratory and after a revised Local Coverage Determination is effective for its California laboratory.
Lucid Diagnostics Inc. reported second quarter 2026 results and a business update focused on its EsoGuard esophageal DNA test. The company recognized $1.5 million in EsoGuard revenue and processed 2,770 EsoGuard tests in the quarter. Management highlighted securing a commercial coverage policy through Concert, recently acquired by Lyric, which deems EsoGuard medically necessary for eligible patients and has been adopted by multiple client health plans, as well as progress with the VA and major health systems.
For the three months ended June 30, 2026, operating expenses were about $14.3 million, including $1.7 million of stock-based compensation. GAAP net loss was approximately $11.7 million, and net loss attributable to common stockholders was about $14.7 million, or $(0.08) per share. Non-GAAP adjusted loss was about $10.9 million, or $(0.06) per share. Cash and cash equivalents were $33.4 million as of June 30, 2026, compared with $34.7 million as of December 31, 2025.
Lucid Diagnostics Inc. reported higher EsoGuard testing revenue but continued significant losses for the quarter and six months ended June 30, 2026. Revenue reached $1.5 million for the quarter and $2.7 million for the first half of 2026, up from $1.2 million and $2.0 million a year earlier.
The company recorded a first-half net loss attributable to common stockholders of $38.3 million and used $23.4 million of cash in operating activities. Cash was $33.4 million and working capital about $9.1 million as of June 30, 2026, including $23.5 million of current 2024 Senior Secured Convertible Notes. Management states that recurring losses, cash burn, and upcoming obligations raise substantial doubt about the company’s ability to continue as a going concern without additional capital and expanded reimbursement.
Lucid raised capital through an April 2026 registered direct offering of 18,000,000 shares for net proceeds of $16.8 million and an at-the-market program adding about $5.3 million. The $21.975 million 12% 2024 Convertible Notes had a fair value of $23.5 million and carry covenants, including a minimum cash requirement of $5.0 million. The company is pursuing Medicare coverage for EsoGuard, obtained its first positive coverage policy from a laboratory benefit manager, and secured a U.S. Department of Veterans Affairs contract.
Lucid Diagnostics Inc. reported results of its annual stockholder meeting, where about 84.7% of shares entitled to vote were represented. Stockholders re-elected three Class B directors, approved an increase in authorized common shares, and ratified the company’s independent auditor.
Authorized common stock rose by 100,000,000 shares, from 300,000,000 to 400,000,000, through an amendment to the certificate of incorporation that became effective upon filing with the Delaware Secretary of State. Stockholders also ratified CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2025.
Lucid Diagnostics Inc. director Dennis Matheis reported an open-market purchase of 245,000 shares of common stock. The weighted average purchase price was $1.0011 per share, with individual trade prices ranging from $0.9375 to $1.0200. Following these purchases, he directly owns 1,033,443 shares.
Lucid Diagnostics Inc. reported first-quarter 2026 results and a business update centered on its EsoGuard esophageal DNA test. The company processed 3,177 EsoGuard tests and generated $1.3 million in EsoGuard revenue for the quarter.
GAAP net loss was approximately $13.9 million, or $(0.17) per common share, including a deemed Preferred Stock dividend that brought net loss attributable to common stockholders to about $23.6 million. Non-GAAP adjusted loss was roughly $10.5 million, or $(0.07) per share.
Lucid ended March 31, 2026 with $27.9 million in cash and cash equivalents and had recently completed an underwritten public offering of common stock, netting about $17 million, resulting in $45 million in proforma cash and a runway extending into 2027. Management emphasized progress toward Medicare coverage, growing EsoGuard demand, and broader engagement with health systems, the VA, and commercial payors.